Hopes are high for a powerful new compound aimed at lowering blood fat levels responsible for potentially fatal heart disease. In a recent trial, the oral drug, TLC-2716, lowered blood triglycerides ...
OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced the publication in Nature ...
OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced positive topline results from a Phase 2a proof-of-concept study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results